EDITAS MEDICINE BUSINESS DEVELOPMENT AND PARTNERING

Editas Medicine holds a large portfolio of foundational U.S. and international patents and is the exclusive licensee of Harvard University’s and the Broad Institute’s Cas9 patent estates covering Cas9 use in developing human medicines and Broad Institute’s Cas12a patent estate covering Cas12a use in developing human medicines. As the exclusive licensee, we are uniquely positioned to issue exclusive and non-exclusive sublicenses for Cas9 and Cas12a to any company seeking to use these enzymes to make human medicines, including in vivo and ex vivo uses.

For further information on licensing Editas’ proprietary editing technologies or the Cas9 and Cas12a patent estates, please contact our business development team.